Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Merck
Colorcon
AstraZeneca
Boehringer Ingelheim

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,474,447

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,474,447 protect, and when does it expire?

Patent 8,474,447 protects ATROVENT HFA and is included in one NDA.

This patent has nine patent family members in eight countries.

Summary for Patent: 8,474,447
Title:Inhaler device
Abstract: The invention relates to a hand-held device (1), as depicted in exemplary FIG. 4, for metered dispensing of sprayable substances, particularly medicaments for inhalation, with a cartridge (3) that can be moved into the dispensing position, by pressure being applied to a housing, and with a step-by-step indexing mechanism (11) which is entrained by the cartridge (3) in the opening travel thereof and which is used to record and display the dispensing actuations that have been performed. In order to suitably design a hand-held device of the type in question with a simplified structure, in such a way that the indexing steps can be performed smoothly and safely without connection to the cartridge, it is proposed that slits (19) extend obliquely only over part of the travel of the step-by-step indexing mechanism housing (34) and that the guide pins (33) guided therein move, over the remainder of the travel of the step-by-step indexing mechanism (11), parallel to the longitudinal axis (x-x) of the step-by-step indexing mechanism.
Inventor(s): Von Schuckmann; Alfred (Kevelaer, DE), Hochrainer; Dieter (Schmallenberg, DE), Hoelz; Hubert (Oberheimbach, DE)
Assignee: Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)
Application Number:12/677,555
Patent Claim Types:
see list of patent claims
Device;

Drugs Protected by US Patent 8,474,447

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim ATROVENT HFA ipratropium bromide AEROSOL, METERED;INHALATION 021527-001 Nov 27, 2004 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,474,447

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2007 045 438Sep 22, 2007
PCT Information
PCT FiledAugust 28, 2008PCT Application Number:PCT/EP2008/061337
PCT Publication Date:March 26, 2009PCT Publication Number: WO2009/037085

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
McKesson
McKinsey
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.